PlateletsMay 20, 2015

Changes in blood clot properties in essential thrombocythemia.

Updated Jan 1, 2026

Abstract

Reduced plasma fibrin clot permeability coefficient (Ks) was observed in patients with essential thrombocythemia (ET), showing a 38% decrease (p < 0.0001).

Fibrin clot lysis time (CLT) was prolonged by 34% (p < 0.0001) in ET patients compared to controls.
ET was associated with a shorter lag phase in fibrin clot formation (5% decrease, p = 0.01) and a higher maximum absorbency of the turbidimetric curve (+6%, p < 0.001).
Patients with ET exhibited significantly higher plasma levels of P-selectin (+193%, p < 0.00001) and platelet factor 4 (PF4) (+173%, p < 0.00001).
Elevated levels of tissue plasminogen activator (t-PA) (+20%, p < 0.001) and plasminogen activator inhibitor-1 (PAI-1) (+23%, p < 0.01) were found in the ET group.
Fibrin clot properties correlated with several biomarkers, including an inverse relationship between Ks and fibrinogen, PF4, and C-reactive protein.

Simplified

Patients with increased thromboembolic risk tend to form denser fibrin clots which are relatively resistant to lysis. We sought to investigate whether essential thrombocythemia (ET) is associated with altered fibrin clot properties in plasma. Ex vivo plasma fibrin clot permeability coefficient (Ks), turbidimetry and clot lysis time (CLT) were measured in 43 consecutive patients with ET (platelet count from 245 to 991 × 10(3)/µL) and 50 control subjects matched for age, sex and comorbidities. Fibrinolysis proteins and inhibitors together with platelet activation markers were determined. Reduced Ks (-38%, p < 0.0001) and prolonged CLT (+34%, p < 0.0001) were observed in ET. The differences remained significant after adjustment for fibrinogen and platelet count. ET was associated with a slightly shorter lag phase (-5%, p = 0.01) and higher maximum absorbency of the turbidimetric curve (+6%, p < 0.001). The ET patients had higher plasma P-selectin by 193% (p < 0.00001) and platelet factor 4 (PF4) by 173% (p < 0.00001), with higher P-selectin observed in 19 (44%) patients with JAK-2 gene V617F mutation. Higher t-PA (+20%, p < 0.001), 23% higher plasminogen activator inhibitor-1, PAI-1 (+23%, p < 0.01) and unaltered thrombin-activatable fibrinolysis inhibitor, plasminogen and α2-antiplasmin activity were found in the ET group. Ks inversely correlated with fibrinogen, PF4 and C-reactive protein. CLT positively correlated only with PAI-1. Patients with ET display prothrombotic plasma fibrin clot phenotype including impaired fibrinolysis, which represents a new prothrombotic mechanism in this disease.

Full Text

Full text is available at the source.

View Full Text ↗

Changes in blood clot properties in essential thrombocythemia.

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the long covid brief